Effects of leucine-enriched essential amino acid supplementation on muscular fatigue and inflammatory cytokines in wheelchair basketball players

Young Hwan An1# / Jisu Kim2,3# / Hee-Jae Kim3 / Kiwon Lim1,2,3*

1. Department of Physical Education, Konkuk University, Seoul, Republic of Korea
2. Department of Sports Medicine and Science in Graduate School, Konkuk University, Seoul, Republic of Korea
3. Physical Activity and Performance Institute, Konkuk University, Seoul, Republic of Korea

# These authors contributed equally to this work.

INTRODUCTION

People with disabilities are at risk of developing secondary health conditions, including high morbidity and mortality1. A sedentary lifestyle occurring soon after spinal cord injury (SCI) may be in contrast to an active physical engagement preinjury and therefore can be associated with profound physical deconditioning sustained throughout the lifespan2. SCI results in an accelerated trajectory of diseases and disorders that resemble those experienced with aging3. Characteristic conditions of this accelerated state include vascular diseases, arterial circulatory insufficiency, atherogenic dyslipidemia, type 2 diabetes, bone and joint diseases and related endocrine disorders, immune dysfunction, and pain of musculoskeletal and neuropathic origins4-8. To overcome these problems, various exercises have been devised to maintain the health of disabled people9,10.

Wheelchair basketball, a typical sport played while in a wheelchair, is similar to regular basketball11. Wheelchair basketball is designed for individuals with physical disabilities such as paralysis, amputation, SCI, or joint and musculoskeletal disorders12. Wheelchair basketball players have to perform highly intense movements, including starting and stopping the wheelchair and turning in different directions using upper body muscles only13. Because they only use small muscles (biceps, back muscles, brachial muscles, etc.) of their upper body while playing, they are not only at risk of early muscle damage and inflammatory response but also of more injuries as compared to regular basketball players who use both upper and lower body muscles at the same time14. Therefore, it is very important for a wheelchair basketball player to prevent early muscle damage and inflammation response and to recover quickly. Prolonged high-intensity exercises are known to induce oxidative stress, fatigue, and tissue injuries such as muscle damage indicated by an increase in creatine kinase (CK) and lactic dehydrogenase (LDH) levels15. Moreover, acute or intense exercise alters the systemic balance of cytokines which are cell signaling molecules associated with oxidative stress16. Cytokine is a type of protein secreted from immune cells such as T cells, B cells, and macrophages, and is involved in the transmission of signals between cells,
control of cell behavior, and immune response. After exercise, initiation of muscle-tissue injury by high-force eccentric contractions promotes infiltration by inflammatory cells. These cells, in conjunction with local muscles, endothelial cells, and satellite cells, produce an array of cytokines to regulate the inflammatory process, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)17.

IL-6 is synthesized and secreted by contraction of skeletal muscle fibers especially during exercise and is the first cytokine released in the circulation18. The serum levels of IL-6 have been found to rise rapidly during prolonged and high-intensity exercise followed by a complete decline to baseline levels thereafter19. The response of IL-6 to exercise has been reviewed as an indicator of muscle damage and a marked increase in circulating levels of IL-6 after intense exercise is a remarkably consistent finding in several studies17,21.

After intensive exercise, reactions that are similar to those caused from infections and injuries could appear in the human body. It has been reported that the blood plasma concentrations of various substances, such as cytokines like TNF-α and IL-6 that affect the function of white blood cells, could increase after intensive exercise20,21. Many researchers believe that the most important variable affecting immune and inflammatory responses is the intensity of the exercise. But reports describing how the muscle damage caused from exercise could be restored are not available24.

Previous studies reported that fatigue and muscle damage caused by exercise could be attenuated with adequate rest and nutrition as skeletal muscle adapted with training18. Therefore, many athletes have been using dietary supplements to prevent fatigue and muscle damage.

Branched-chain amino acids (BCAAs) are usually consumed as nutritional supplements by many athletes and people involved in regular and moderate physical activities regardless of their practice level. Unlike other amino acids, BCAAs, which consist of leucine, isoleucine, and valine, can be involved in energy production, an important aspect of muscle metabolism25.

Leucine is well known for stimulating mammalian target of rapamycin (mTOR), also known as a potent stimulator of protein synthesis26. Several studies have demonstrated that mTOR is not only a key pathway in inflammation-dependent muscle regeneration, but overexpression of mTOR has been found to reduce inflammation in cardiomyocytes and prevent cardiac dysfunction27. Moreover, a potent mTOR inhibitor, rapamycin, impairs muscle regeneration after injury28. Accordingly, some reports have also shown that the intake of leucine-enriched essential amino acid (LEAA) enhances recovery from fatigue and muscle repair by modulating inflammation29,31.

Despite these positive effects of LEAA, previous studies mainly evaluated the effects of LEAA on athletes without disabilities. Thus, we investigated the effects of LEAA ingestion on the level of muscle damage, inflammation, and delayed-onset muscle soreness (DOMS) in wheelchair basketball players after a basketball game and interval training.

### METHODS

#### Participants

The participants’ characteristics are shown in Table 1. Ten male wheelchair basketball athletes with SCI and amputation participated in this study. The participants were selected from top-ranking teams in the Korean Paralympic wheelchair basketball league. The study design, purpose, and possible risks were explained to each participant before written consent was obtained. Out of the ten athletes, nine participated in the final test, while one athlete was not able to participate due to injury. All participants were restricted from engaging in vigorous physical exercises prior to the experiments. They were also strongly requested to continue their regular dietary habits, especially the intake of protein and food supplement during the experiments. All experiments were approved by the institutional review board of Konkuk University (IRB no.: 7001355-201606-HR-124).

#### Leucine-enriched essential amino acid supplement (LEAA supplement)

The LEAA supplement (Ajinomoto Co., Inc., Tokyo, Japan) contained 4.0 g of a mixture of 9 essential amino acids (leucine, 1.61 g; lysine, 0.67 g; valine, 0.44 g; isoleucine, 0.43 g; threonine, 0.37 g; phenylalanine, 0.27 g; methionine, 0.13 g; histidine, 0.07 g; and tryptophan, 0.03 g) per pack. By contrast, the placebo contained 4.0 g of

### Table 1. Individual anthropometric data, lesion levels, and point values.

| Participants (N=9) | Age (years) | Height (cm) | Weight (kg) | BMI (kg/m²) | Body fat (%) | Lesion levels | Point values* |
|--------------------|-------------|-------------|-------------|-------------|--------------|---------------|---------------|
| 1                  | 40          | 177.8       | 65          | 20.6        | 11.7         | Amputation    | 4.5           |
| 2                  | 28          | 179.7       | 68          | 21.1        | 15.6         | SCI 12        | 3.0           |
| 3                  | 24          | 180.4       | 102         | 31.3        | 13.0         | Amputation    | 4.0           |
| 4                  | 36          | 163.0       | 55          | 20.7        | 19.8         | SCI 10        | 2.0           |
| 5                  | 37          | 177.3       | 83          | 26.4        | 28.0         | SCI 6         | 1.0           |
| 6                  | 28          | 170.0       | 53          | 18.3        | 18.8         | SCI           | 2.0           |
| 7                  | 33          | 181.0       | 83          | 25.2        | 21.1         | Polio         | 4.0           |
| 8                  | 23          | 173.0       | 70          | 23.4        | 25.9         | SCI 11        | 2.0           |
| 9                  | 37          | 178.7       | 95          | 29.7        | 23.4         | SCI 7         | 1.0           |
| M±SD               | 34.5±5.9    | 175.6±5.9   | 74.8±16.9   | 24.0±4.42   | 18.6±4.95    | -             | -             |

All values are presented as mean ± standard deviation. BMI, Body mass index; SCI, Spinal cord injury. * Point value for each player: 1.0–4.5 (highest to least impact of impairment).
Effect of LEAA on muscular fatigue inflammatory cytokines in wheelchair basketball players

maltodextrin per pack. Both supplements were processed such that they were indistinguishable based on their external appearance and taste. The composition of LEAA was based on previous studies, which reported that LEAA promotes muscle protein synthesis when ingested\textsuperscript{32,33}. The amount of LEAA (3 times of 4.0 g/day), timing, and duration of ingestion were based on a previous study, which revealed that ingestion of supplements containing 12 amino acids attenuated muscle damage after exercise\textsuperscript{27}. The supplements were ingested along with 200 ml of water.

**Experimental design**

The research design is shown in Figure 1. All participants were exposed to LEAA or placebo treatment in a double-blind, randomized, crossover experiment. The experiment was conducted in two 5-day phases, with a 4-week washout period. On the first day, the participants were involved in a four 12-min quarter basketball game and interval training, five 28-m sprints, five 28-m 4-step go and stop run, and three forward and backward run with one player. Within the 4-day recovery period, mild training programs were conducted. Exercise intensity was assessed after the basketball game and interval training by monitoring heart rate (Polar, Stanford, CT, USA), ratings of perceived exertion, and lactate levels (Lactate Pro 2, Arkray, Tokyo, Japan). Exercise programs were same in both phases.

Blood samples were collected every morning after at least 8 h of fasting. Samples were collected on the first day of each period. On the first day, all participants performed vigorous physical exercises and took LEAA or placebo 30 min before the game, after the interval training, and between dinner and bedtime. For the rest of the experiment period, the participants took LEAA or placebo every morning, at 3 pm, and before bedtime. The placebo was exactly same in shape and weight, indistinguishable from the LEAA supplement.

**Blood sample analysis**

All study participants were restricted from drinking and engaging in intense physical activity 48 h prior to the study. They also fasted for 8 h, except for fluid intake, before the blood was drawn. Approximately 10 ml of blood was drawn using a disposable syringe and collected into two 5-ml SST and ethylenediaminetetraacetic acid vacutainer tubes. The blood samples were spun in the centrifuge for 15 min at the speed of 3000 rpm right after the collection. Then, the separated serum and plasma were kept at −70 °C until further use. Muscle damage was evaluated based on plasma CK levels (Bioclin Diagnos-
tics, Sao Paulo, Brazil), which was performed according to the method established by Oliver. To evaluate inflammatory cytokine levels, IL-6 and TNF-α levels were measured with enzyme immunoassay method using ELx50 (an automatic washing system) and SIRIO-S (a microplate photometer equipped with a 450 nm/620 nm filter, BioTek Inc., USA). The reagents used to measure IL-6 and TNF-α high sensitivity were IL-6 (Bender MedSystem, Germany) and TNF-α (Bender MedSystem, Germany).

Muscle soreness
Muscle soreness was measured using visual analogue scale (VAS), a valid and reliable pain measurement methods proven by many previous studies. On a 100-mm horizontal line, a 0 measurement on the left end means no pain at all, while a 100 measurement on the right end means maximum pain. In the study, participants were asked to indicate the measure of their pain on the VAS in six different areas of the body – whole body, forearm, upper arm, shoulder, back, and abdomen, 4 days after recovering from a basketball game and an interval training.

Statistical analysis
All data are expressed as mean ± standard deviation. The change in values was calculated by subtracting the baseline value from that on each recovery days (days 1, 2, 3, and 4) in CK, IL-6, and TNF-α. The relative data was calculated by dividing the value for each recovery period by the day 1 value (VAS not measured at baseline) and then multiplied by 100 [e.g., day 3 = (day 3 / day 1) × 100]. A two-way (two groups × 5 recovery days) repeated measure analysis of variance (ANOVA) was used to determine the main and interaction effects among groups and the recovery days for mean inflammatory cytokine (IL-6 and TNF-α) and muscle damage (CK) change from baseline value, using SPSS version 21.0 (IBM, USA). The assumption of sphericity was tested by Mauchly’s test. If sphericity assumption was violated, the Greenhouse-Geisser correction was used. Post-hoc test used the least significant difference to evaluate the main and interaction effects. In the VAS, Cohen’s effect size was used to express the statistical significance. The alpha level was set at 0.05.

RESULTS
Heart rate, rating of perceived exertion, and lactate levels during exercise
In the study, the heart rate increased with the increase in workload during the exercise test (basketball play and interval training) in both trials (Table 2). The basketball game and interval training were performed with high intensity (approximately 150–164 bpm of 70%–80% of heart rate reserve; no data presented). No significant difference was observed in the mean heart rate (LEAA: 146.3 ± 6.0 bpm; placebo: 143.8 ± 3.9 bpm) and peak heart rate (LEAA: 182.1 ± 6.9 bpm; placebo: 176.3 ± 10.6 bpm) between the groups during the game. Moreover, no significant difference was observed in the mean heart rate (LEAA: 143.77±11.68 bpm; placebo: 139.50 ± 7.76 bpm) and peak heart rate (LEAA: 170.66 ± 6.70 bpm; placebo: 173.87 ± 5.48 bpm) between the LEAA and placebo trials during the interval training. The rating of perceived exertion was not significantly different between the LEAA and placebo groups during the game (LEAA: 14.44 ± 1.87; placebo: 13.89 ± 1.61) and during the interval training (LEAA: 16.88 ± 2.10; placebo: 16.67±1.87). There was no significant difference in the lactate concentrations between the LEAA and placebo groups during the resting phase (LEAA: 2.93 ± 1.59 mmol; placebo: 2.71 ± 1.39 mmol) after the game (LEAA: 5.42 ± 2.15 mmol; placebo: 5.92 ± 2.52 mmol), and after the interval training (LEAA: 11.04 ± 5.16 mmol; placebo: 9.78 ± 5.39 mmol).

| Variables | Placebo (N=9) | LEAA (N=9) | P |
|-----------|--------------|------------|---|
| HR rest (bpm) | 65.1 ± 8.5 | 65.1 ± 8.5 | .913 |
| HR mean during game (bpm) | 143.9 ± 4.0 | 143.9 ± 4.0 | .343 |
| HR peak during game (bpm) | 176.4 ± 10.6 | 176.4 ± 10.6 | .203 |
| HR mean during interval (bpm) | 139.5 ± 7.8 | 139.5 ± 7.8 | .395 |
| HR peak during interval (bpm) | 173.9 ± 5.5 | 173.9 ± 5.5 | .301 |
| RPE during game | 13.9 ± 1.6 | 13.9 ± 1.6 | .511 |
| RPE during interval | 16.7 ± 1.9 | 16.7 ± 1.9 | .832 |
| Lactate rest (mmol) | 2.7 ± 1.4 | 2.7 ± 1.4 | .757 |
| Lactate after game (mmol) | 5.9 ± 2.5 | 5.9 ± 2.5 | .657 |
| Lactate after interval (mmol) | 9.8 ± 5.4 | 9.8 ± 5.4 | .621 |

| Blood parameter of muscle damage and inflammation |

The serum CK activities throughout the experimental period, which served as a blood parameters of muscle damage, are presented in Figure 2. On the first day of recovery, serum CK levels tended to be lower in the LEAA intake group than in the placebo group (p = .0.668). However, there was no significant difference in CK levels during the recovery period between the LEAA and placebo groups (days 1, 2, 3, and 4). CK levels peaked on recovery day 1 (LEAA: 88.9 ± 31.5 IU/L; placebo: 104.6 ± 41.9 IU/L) and day 3 (LEAA: 158.3 ± 58.7 IU/L; placebo: 167.3 ± 59.5 IU/L) in both groups after the basketball game and interval training.

The serum TNF-α and IL-6 levels, which served as blood parameters of inflammation, are presented in Figure 2. The TNF-α in the LEAA group peaked on day 1 and rapidly decreased during the recovery period. On the contrary, the serum TNF-α levels in the placebo group peaked on day 3 and were higher than those in the LEAA group. However, there were no significant differences in TNF-α levels between the two groups (time: 0.001; group: 0.340; interaction: 0.256). Serum IL-6 was signifi-
Effect of LEAA on muscular fatigue inflammatory cytokines in wheelchair basketball players

**Figure 2.** Changes in blood parameters of muscle damage and inflammation. Graph showing mean CK, TNF-α, and IL-6 from the baseline of the placebo and LEAA groups within the 4-day recovery period (after the basketball games and interval training). Data expressed as mean ± SD (n = 9 in each group). P values indicated using two-way repeated measures ANOVA.

**Figure 3.** Visual analogue scale of muscle fatigue. Graph showing the changes in mean VAS values of the placebo and LEAA groups from day 1 within the 4-day recovery period (after the basketball games and interval training). Data expressed as mean ± SD (n = 9 in each group). Effect size indicated using Cohen’s d.
Effect of LEAA on muscular fatigue and inflammatory cytokines in wheelchair basketball players

Psychologically increased after exercise in both LEAA and placebo groups. A two-way ANOVA with repeated measures for IL-6 showed that time had a significant effect (P = .040) on IL-6 levels (P = .028), while group-by-time interactions (P = .554) did not.

DAMS following exercise

Figure 3 shows the VAS scores for subjective DOMS assessment. The VAS scores of all examined areas (whole body, forearm, upper arm, shoulder, back, and abdomen) had no significant difference between the LEAA and placebo groups with repeated measures ANOVA during the recovery period (days 1, 2, 3, and 4). However, the VAS scores in the whole body and back peaked on Day 1 and then rapidly decreased in the LEAA group, whereas the VAS scores in the placebo group peaked on days 2 and 3 and did not subside compared with those in the LEAA group. Furthermore, there was a significant improvement in the relative values for the whole body (day 1, d = 0.40; Day 4, d = 1.23) and back soreness (day 4, d = 1.73) as shown in the effect size analysis with Cohen’s d in the LEAA groups (Figure 3).

DISCUSSION

The study was designed to identify the impact of LEAA ingestion on muscle damage and inflammatory response in disabled wheelchair basketball players. The present findings indicated that LEAA ingestion suppressed circulating IL-6 levels. Furthermore, LEAA improved the recovery of whole body and back soreness after the game/interval training within the 4-day recovery period. However, there was no significant difference between the TNF-α and CK levels.

Several studies have reported that CK is one of the markers of exercise-induced muscle damage, and in general, intense physical exercise is believed to increase CK levels in blood. In our study, both groups showed an increase in CK levels from baseline after the wheelchair basketball game and interval training. On the first day of recovery, serum CK levels tended to be lower in the LEAA intake group than in the placebo group. This trend could be a factor that effectively reduces the CK level, increased during high-intensity exercise. However, compared with the placebo group, LEAA ingestion did not reduce the CK levels during the recovery period. Contrary to our results, Matsumoto K et al. reported that the plasma CK, LDH, and granulocyte elastase levels after the training program in the BCAA trial on 12 long-distance runners (20 ± 1 years) were lower than those in the placebo group (−21%, −6%, and −15%, respectively). In addition, Kim DH et al. reported that BCAA ingestion reduced the CK and LDH levels after the cycle exercise (at 70% VO2 max) to exhaustion. However, in this study, we could not detect the effectiveness of LEAA ingestion with regard to CK values. This is because the CK value varies greatly depending on the sampling point. According to a recently published review paper, it appeared that a high volume of upper body exercise with short rest intervals taken between sets was more likely to produce the greatest increase in CK levels. In our study, total serum CK activity was markedly elevated 24 h after the exercise bout and gradually returned to baseline levels. Although the participants were wheelchair basketball players who frequently used their upper body for movement and practice, CK samples were obtained 24 h after performing the exercise. In addition, there were two more possible reasons for the insufficient CK elevation. One might be the insufficient intensity of exercise and the other reason might be the fact that plasma CK in trained athletes is less likely to elevate by exercise. For these reasons, the effect of LEAA supplementation on CKs could not be confirmed in this study.

Cytokines control the immune and inflammatory response. Skeletal muscle inflammation can increase the expression and activity of factors such as TNF-α, ROS, and IL-6, which in turn could contribute to protein degradation and attenuate protein synthesis. By contrast, BCAA supplementation could counteract such effects by suppressing skeletal muscle proteolysis and stimulating protein synthesis. Our study revealed that LEAA attenuated IL-6 expression. Nosaka et al. reported that resistance training with BCAA ingestion decreased the inflammatory response and muscle soreness. Furthermore, Bassit et al. found that ingestion of BCAA (6.0 g of 60% L-leucine, 20% L-valine, and 20% L-isoleucine/day) decreased the inflammatory response and muscle soreness after the triathlon game (Olympic triathlon: a 1.5-km swim, a 40-km bike, and a 10-km run). The recent reports demonstrated mTOR as a key pathway in inflammation-dependent muscle regeneration. Kato et al. reported that LEAA accelerated recovery from muscle damage by preventing excessive inflammation and IL-6 expression by stimulating the mTOR. Additionally, Dreyer et al. and Pasiakos et al. reported that LEAA stimulated muscle protein synthesis after performing several types of exercises. Therefore, LEAA may have sufficient biological activity to promote post-exercise recovery by increasing protein synthesis.

The TNF-α values of the LEAA group were lower than those of the placebo group, but no significant differences were found. A large number of intense, eccentric muscle action during team sports can cause muscle damage of varying degrees and may trigger inflammatory responses. In the players of team sports, TNF-α levels are typically elevated. The participants of this study were athletes who had SCI or amputation. As previously reported, they also had immune system disorders due to deterioration in white blood cell count. BCAA or leucine amino acids suppress DOMS, which is a typical symptom of muscle damage. DOMS is the pain felt in the skeletal muscles upon palpation or movement following exercise, which generally peaks within 24–48 h. Shimomura Y et al. reported 12 young, untrained females who ingested 100 mg/kg body weight of BCAA before the squat exercise.
DOMS peaked on days 2 and 3 in both trials (BCAA and control; dextrin), and the level of soreness was significantly lowered in the BCAA trial than in the control group. In our study, the prevalence of whole-body fatigue after the event was highest on day 2 and back on day 3 but was lower on day 4 in the LEAA group. The sense of fatigue was similar to that of muscle soreness after performing an exercise. Previous studies reported that muscle soreness was a typical consequence of eccentric exercise-induced muscle damage; however, the underlying mechanism of muscle soreness is not clearly understood. It is assumed as an inflammatory response to muscle damage.

Despite several research to evaluate the effects of BCAA, no study has reported the effects of BCAA on patients with disabilities and healthy athletes. In recent years, researchers found that BCAA ingestion reduced muscle fiber disruption, resulting in lower peak values of serum IL-6 and CK after exercise training. In particular, leucine, a component of BCAA, has been known to play the key role in activating the mTOR signaling pathway and inducing muscle synthesis. mTOR signaling pathway serves as a central regulator of cell growth and proliferation through protein synthesis. It is also known to control differentiation and fusion of skeletal muscles that may increase the size of the muscle cells. Bolster et al. reported the muscle regeneration process was regulated by the mTOR pathway. Kato et al. investigated the effects of LEAA, as a potent mTOR stimulator on muscle soreness. Several studies have indicated that consuming L-leucine may significantly increase muscle protein synthesis and decrease proteolysis during exercise training, which indicates a dose-dependent effect of leucine on muscle protein synthesis. This is the first study to examine the effects of LEAA ingestion on muscle damage and muscle soreness in wheelchair basketball players. Future studies should be conducted to establish the BCAA intake capacity according to the level of disability or injury. In conclusion, LEAA ingestion may reduce muscle fatigue (DOMS) and inflammatory response (IL-6) during the recovery period after an intense exercise.

Despite the numerous studies conducted to evaluate the effects of LEAA, the effectiveness of LEAA in disabled athletes has not yet been examined. Our results revealed that LEAA supplementation before and after intense exercise session could help reduce muscle soreness and inflammatory response in wheelchair basketball players. Further studies are required to identify the mechanisms responsible for the effects of LEAA supplementation in disabled athletes.

ACKNOWLEDGMENTS

This paper was supported by the KU Research Professor Program of Konkuk University.

REFERENCES

1. Hollar DW Jr. Disability and health outcomes in geospatial analyses of Southeastern U.S. county health data. Disabil Health J. 2017;10:518-24.
2. Maher JL, McMillan DW, Nash MS. Exercise and health-related risks of physical deconditioning after spinal cord injury. Top Spinal Cord Inj Rehabil. 2017;23:175-87.
3. Silveira SL, Ledoux TA, Robinson-Whelen S, Stough R, Nosek MA. Methods for classifying obesity in spinal cord injury: a review. Spinal Cord. 2017;55:812-7.
4. Dearwater SR, LaPorte RE, Robertson RJ, Brenes G, Adams LL, Becker D. Activity in the spinal cord-injured patient: an epidemiologic analysis of metabolic parameters. Med Sci Sports Exerc. 1986;18:541-4.
5. Nash MS, Mendez AJ. A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. Arch Phys Med Rehabil. 2007;88:751-7.
6. Phillips WT, Krall BJ, Sarkarati M, Weraarchakul G, Myers J, Franklin BA, Parkash I, Froelicher V. Effect of spinal cord injury on the heart and cardiovascular fitness. Curr Probl Cardiol. 1998;23:641-716.
7. Hopman MT, Monroe M, Dueck C, Phillips WT, Skinner JS. Blood redistribution and circulatory responses to submaximal arm exercise in persons with spinal cord injury. Scand J Rehabil Med. 1998;30:167-74.
8. Hjeltnes N. Oxygen uptake and cardiac output in graded arm exercise in paraplegics with low level spinal lesions. Scand J Rehabil Med. 1977;9:107-13.
9. Jeng SC, Chang CW, Liu WY, Hou YJ, Lin YH. Exercise training on skill-related physical fitness in adolescents with intellectual disability: a systematic review and meta-analysis. Disabil Health J. 2017;10:198-206.
10. Shapiro DR, Malone LA. Quality of life and psychological affect related to sport participation in children and youth athletes with physical disabilities: a parent and athlete perspective. Disabil Health J. 2016;9:385-91.
11. Uzun S, Pourmoghaddam A, Hieronymus M, Thrasher TA. Evaluation of muscle fatigue of wheelchair basketball players with spinal cord injury using recurrence quantification analysis of surface EMG. Eur J Appl Physiol. 2012:112:3847-57.
12. van der Woude LH, van Cronenborg JJ, Wolff I, Dallmeijer AJ, Hollander AP. Physical work capacity after 7 wk of wheelchair training: effect of intensity in able-bodied subjects. Med Sci Sports Exerc. 1999;31:331-41.
13. International Wheelchair Basketball Federation. http://www.iwbf.org/ (2012). Accessed 20 Sept 2017.
14. Matsumoto K, Koba T, Hamada K, Sakurai M, Higuchi T, Miya-ta H. Branched-chain amino acid supplementation attenuates muscle soreness, muscle damage and inflammation during an intensive training program. J Sports Med Phys Fitness. 2009;49:424-31.
Effect of LEAA on muscular fatigue inflammatory cytokines in wheelchair basketball players

15. Baird MF, Graham SM, Baker JS, Bickerstaff GF. Creatine-kinase- and exercise-related muscle damage implications for muscular performance and recovery. J Nutr Metab. 2012;2012:960363.

16. Tajra V, Tibana RA, Vieira DC, de Farias DL, Teixeira TG, Funghetto SS, Silva AO, de Sousa NM, Willardson J, Karnikowski MG, Prestes J. Identification of high responders for interleukin-6 and creatine kinase following acute eccentric resistance exercise in elderly obese women. J Sci Med Sport. 2014;17:662-6.

17. Miles MP, Pearson SD, Andring JM, Kidd JR, Volpe SL. Effect of carbohydrate intake during recovery from eccentric exercise on interleukin-6 and muscle-damage markers. Int J Sport Nutr Exerc Sci. 2007;17:507-20.

18. Hennigar SR, McClung JP, Pasiakos SM. Nutritional interventions and the IL-6 response to exercise. FASEB J. 2017;31:3719-28.

19. Pedersen BK, Åkerström TC, Nielsen AR, Fischer CP. Role of myokinase in exercise and metabolism. J Appl Physiol. 2007;103:1093-8.

20. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16:1335-47.

21. Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev. 2005;33:114-9.

22. Giannini S, Nobile M, Sella S, Dalle Carbonare L. Bone disease in primary hypercalciuria. Citt Rev Clin Lab Sci. 2005;42:229-48.

23. Inanir A, Ozoran K, Tütük H, Memerci B. The effects of calciotin therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res. 2004;32:570-82.

24. Gleeson M, Nieman DC, Pedersen BK. Exercise, nutrition and immune function. J Sports Sci. 2004;22:115-25.

25. Fouré A, Bendahan D. Is branched-chain amino acids supplementation an efficient nutritional strategy to alleviate skeletal muscle damage? A Systematic Review. Nutrients. 2017;9:1047.

26. Crozier SJ, Kimball SR, Emmert SW, Anthony JC, Jefferson LS. Oral leucine administration stimulates protein synthesis in rat skeletal muscle. J Nutr. 2005;135:376-82.

27. Song X, Kusakari Y, Xiao CY, Kinsella SD, Rosenberg MA, Scherrer-Crosbie M, Hara K, Rosenzweig A, Matsui T. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am J Physiol Cell Physiol. 2010;299:C1256-66.

28. Ge Y, Wu AL, Wames C, Liu J, Zhang C, Kawasaki H, Terada N, Boppart MD, Schoenherr CJ, Chen J. mTOR regulates skeletal muscle regeneration in vivo through kinase-dependent and kinase-independent mechanisms. Am J Physiol Cell Physiol. 2009;297:C1434-44.

29. Kirby TJ, Tripplett NT, Haines TL, Skinner JW, Fairbrother KR, McBride JM. Effect of leucine supplementation on indices of muscle damage following drop jumps and resistance exercise. Amino Acids. 2012;42:1897-96.

30. Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL, Chinks DL, Dhanani S, Voepi J, Rasmussen BB. Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocrinol Metab. 2008;294:E392-400.

31. Kato H, Miura K, Nakano S, Suzuki K, Bannai M, Inoue Y. Leucine-enriched essential amino acids attenuate inflammation in rat muscle and enhance muscle repair after eccentric contraction. Amino Acids. 2016;48:2145-55.

32. Bassit RA, Sawada LA, Bacacau RF, NAVarro F, Martins EJ, Santos RV, Capuruto EC, Rogeri P, Costa Rosa LF. Branched-chain amino acid supplementation and the immune response of long-distance athletes. Nutrition. 2002;18:376-9.

33. Jackman SR, Wilard OC, Jeukendrup AE, Tipton KD. Branched-chain amino acid ingestion can ameliorate soreness from eccentric exercise. Med Sci Sports Exerc. 2010;42:962-70.

34. OLIVER IT. A spectrophotometric method for the determination of creatine phosphokinase and myokinase. Biochem J. 1955;61:116-22.

35. Sellwood KL, Brunker P, Williams D, Nicol A, Hinman R. Ice-water immersion and delayed-onset muscle soreness: a randomised controlled trial. Br J Sports Med. 2007;41:392-7.

36. Close GL, Ashton T, Cable T, Doran D, Holloway C, Mc Ardle F, MacLaren DPM. Ascorbic acid supplementation does not attenuate post-exercise muscle soreness following muscle-damaging exercise but may delay the recovery process. Br J Nutr. 2006;95:976-81.

37. Nicol LM, Rowlands DS, Fahakerly R, Kellet J. Curcumin supplementation likely attenuates delayed onset muscle soreness (DOMS). Eur J Appl Physiol. 2015;115:1789-77.

38. Koch AJ, Pereira R, Machado M. The creatine kinase response to resistance exercise. J Musculoskelet Neurol Interact. 2014;14:68-77.

39. Kim DH, Kim SH, Jeong WS, Lee HY. Effect of BCAA intake during endurance exercises on fatigue substances, muscle damage substances, and energy metabolism substances. J Exerc Nutrition Biochem. 2013;17:169-80.

40. Brancaccio P, Maffulli N, Limongelli FM. Creatine kinase monitoring in sport medicine. Br Med Bull. 2007;81:82-209-30.

41. Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. Trends Endocrinol Metab. 2016;27:335-47.

42. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol. 2015;11:86-97.

43. Wolfe RR. Branched-chain amino acids and muscle protein synthesis in humans: myth or reality? J Int Soc Sports Nutr. 2017;14:30.

44. Nosaka K, Sacco P, Mawatari K. Effects of amino acid supplementation on muscle soreness and damage. Int J Sport Nutr Exerc Metab. 2006;16:620-35.

45. Pasiakos SM, McClung HL, McClung JP, Margolis LM, Anderson NE, Cloutier GJ, Pikosky MA, Rood JC, Fielding RA, Young AJ. Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis. Am J Clin Nutr. 2011;94:809-18.

46. Souglis A, Bogdanis GC, Giannopoulou I, Papadopoulos Ch, Apostolidis N. Comparison of inflammatory responses and muscle damage indices following a soccer, basketball, volleyball and handball game at an elite competitive level. Res Sports Med. 2015;23:59-72.
47. Loerakker S, Huisman ES, Seelen HA, Glatz JF, Baaijens FP, Oomens CW, Bader DL. Plasma variations of biomarkers for muscle damage in male nondisabled and spinal cord injured subjects. J Rehabil Res Dev. 2012;49:361-72.

48. Leahy DT, Pintauro SJ. Branched-chain amino Acid plus glucose supplement reduces exercise-induced delayed onset muscle soreness in college-age females. ISRN Nutr. 2013;2013:921972.

49. Shimomura Y, Inaguma A, Watanabe S, Yamamoto Y, Muramatsu Y, Bajotto G, Sato J, Shimomura N, Kobayashi H, Mawatari K. Branched-chain amino acid supplementation before squat exercise and delayed-onset muscle soreness. Int J Sport Nutr Exerc Metab. 2010;20:236-44.

50. Shimomura Y, Yamamoto Y, Bajotto G, Sato J, Murakami T, Shimomura N, Kobayashi H, Mawatari K. Nutraceutical effects of branched-chain amino acids on skeletal muscle. J Nutr. 2006;136:529S-32S.

51. Cheung K, Hume P, Maxwell L. Delayed onset muscle soreness: treatment strategies and performance factors. Sports Med. 2003;33:145-64.

52. Paddon-Jones D, Sheffield-Moore M, Zhang XJ, Volpi E, Wolf SE, Aarsland A, Ferrando AA, Wolfe RR. Amino acid ingestion improves muscle protein synthesis in the young and elderly. Am J Physiol Endocrinol Metab. 2004;286:E321-8.

53. Wolfe RR. Effects of amino acid intake on anabolic processes. Can J Appl Physiol. 2001;26 Suppl:S220-7.

54. Ge Y, Chen J. Mammalian target of rapamycin (mTOR) signaling network in skeletal myogenesis. J Biol Chem. 2012;287:43928-35.

55. Bolster DR, Kubica N, Crozier SJ, Williamson DL, Farrell PA, Kimball SR, Jefferson LS. Immediate response of mammalian target of rapamycin (mTOR)-mediated signalling following acute resistance exercise in rat skeletal muscle. J Physiol. 2003;553(Pt 1):213-20.

56. Kato H, Suzuki H, Mimura M, Inoue Y, Sugita M, Suzuki K, Kobayashi H. Leucine-enriched essential amino acids attenuate muscle soreness and improve muscle protein synthesis after eccentric contractions in rats. Amino Acids. 2015;47:1193-201.

57. Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol. 2013;14:133-9.

58. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab. 2006;291:E381-7.